Clinical trial
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction…
NCT00256321 · University of California, Irvine, Other · Terminated
Key facts
| NCT number | NCT00256321 |
|---|---|
| Title | Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma |
| Official title | A Phase II Study of Celecoxib/Oxaliplatin/Capecitabine Combination Chemotherapy for Unresectable,Recurrent, or Metastatic Gastric/Gastroesophageal Junction Carcinoma |
| Lead sponsor | University of California, Irvine, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Carcinoma, Gastroesophageal Junction Carcinoma |
| Intervention type | Drug |
| Interventions | Oxaliplatin, Capecitabine, Celecoxib |
| Enrollment | 4 |
| Start date | Oct 1, 2004 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | Feb 8, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: